Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases

1. A method for treating a bacterial infection caused by Clostridium difficile , comprising the step of administering to a patient in need thereof an oxazolidinone-quinolone hybrid at an infusion rate of from 0.4 to 3 mg/(kg body weight×hour), wherein the oxazolidinone-quinolone hybrid is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:

or a salt thereof.

2. The method according to claim 1 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 20 min to 24 h per day.

3. The method according to claim 1 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 20 min to 5 h per day.

4. The method according to claim 1 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 4 h to 12 h per day.

5. The method according to claim 1 wherein the infusion rate is from 0.4 to 1.5 mg/(kg body weight×h).

6. The method according to claim 1 wherein the infusion rate is from 0.4 to 0.75 mg/(kg body weight×h).

7. The method according to claim 1 , wherein the oxazolidinone-quinolone hybrid is the sodium salt of 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid.

8. The method according to claim 1 , wherein the bacterial infection caused by Clostridium difficile is a gastro-intestinal infection caused by Clostridium difficile.

9. The method according to claim 8 , wherein the bacterial infection caused by Clostridium difficile is an intestinal disease caused by Clostridium difficile.

10. The method according to claim 9 , wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.

11. The method according to claim 1 , wherein the bacterial infection caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.

12. A method for treating a gastro-intestinal infection caused by Clostridium difficile , comprising the step of administering to a patient in need thereof an oxazolidinone-quinolone hybrid at an infusion rate of from 0.4 to 3 mg/(kg body weight×hour), wherein the oxazolidinone-quinolone hybrid is a sodium salt of 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:

or a salt thereof.

13. The method according to claim 12 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 20 min to 24 h per day.

14. The method according to claim 12 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 20 min to 5 h per day.

15. The method according to claim 12 wherein the oxazolidinone-quinolone hybrid is administered over a period of from 4 h to 12 h per day.

16. The method according to claim 12 wherein the infusion rate is from 0.4 to 1.5 mg/(kg body weight×hour).

17. The method according to claim 12 wherein the infusion rate is from 0.4 to 0.75 mg/(kg body weight×hour).

18. The method according to claim 12 , wherein the gastro-intestinal infection caused by Clostridium difficile is an intestinal disease caused by Clostridium difficile.

19. The method according to claim 18 , wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.

20. The method according to claim 12 , wherein the gastro-intestinal infection caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.